Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation

Veera Raghava Raju THUMMALA * ¹, Satya Sankarsana Jagan Mohan THARLAPU ¹, Vijay Kumar REKULAPALLI ¹, Mrutyunjaya Rao IVATURI ², Someswara Rao NITTALA ²

¹ Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad-500 072, India.
² School of Chemistry, Andhra University, Visakhapatnam-530003, A.P., India.

* Corresponding author. E-mail: tvr_raju@rediffmail.com (V. R. R. Thummala)

Sci Pharm. 2014; 82: 99–115    doi:10.3797/scipharm.1309-06
Published: October 21st 2013    Received: September 16th 2013
Accepted: October 21st 2013

This article is available from: http://dx.doi.org/10.3797/scipharm.1309-06
© Thummala et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A sensitive, stability-indicating gradient RP-HPLC method with PDA detection has been developed for the simultaneous analysis of drotaverine impurities in active pharmaceutical ingredient (API) and pharmaceutical formulations. Efficient chromatographic separation was achieved on an XTerra RP18, 150 × 4.6 mm, 5 µm column using gradient elution at 230 nm detection wavelength. The optimized mobile phase consisted of a 0.02 M potassium dihydrogen orthophosphate buffer of pH 3.0 as solvent A and acetonitrile as solvent B. The flow rate of the mobile phase was 1.0 mL min⁻¹ with a column temperature of 25°C. The method showed linearity over the range of 0.251–10.033 µg/mL, 0.231–9.995 µg/mL, 0.230–10.089 µg/mL, 0.334–10.011 µg/mL, and 0.324–10.050 µg/mL for impurities 1, 2, 3, 4, and drotaverine, respectively, with a correlation coefficient greater than 0.999. The relative retention times and relative response factors of impurities 1, 2, 3, 4 were 0.36, 0.90, 1.42, 1.55 and 1.04, 0.84, 1.10, 1.30, respectively. The drotaverine formulation sample was subjected to the stress conditions of acid, base, oxidative, thermal, humidity, and photolytic degradation. Drotaverine was found to degrade significantly in peroxide, base, and heat stress conditions. The degradation products were well-resolved from drotaverine and its impurities. The peak purity test results confirmed that the
drotaverine peak was homogenous and pure in all stress samples and the mass balance was found to be more than 98%, thus proving the stability-indicating power of the method. The developed method was validated according to ICH guidelines with respect to specificity, linearity, limit of detection and quantification, accuracy, precision, and robustness.

Keywords
Drotaverine • RP-HPLC • Stability-indicating • Impurities • ICH guidelines

Introduction
Drotaverine (Fig. 1) is chemically known as 1-(3,4-diethoxybenzylidene)-6,7-dieithoxy-1,2,3,4-tetrahydroisoquinoline [1]. Drotaverine hydrochloride is a highly potent spasmolytic agent [2]. It acts as an antispasmodic agent by inhibiting the phosphodiesterase IV enzyme, specific for smooth muscle spasms and pain, and used to reduce excessive labor pains [3].

The impurity profile of API and pharmaceutical formulations is one of the most challenging tasks of pharmaceutical analytical chemists under industrial environmental conditions [4]. The presence of unwanted or in certain cases unknown chemicals, even in small amounts, may influence not only the therapeutic efficacy, but also the safety of the pharmaceutical products [5]. For these reasons, all major international pharmacopoeia have established maximum allowed limits for related compounds for both bulk and formulated APIs. As per the requirements of various regulatory authorities, the impurity profile study of drug substances and drug products has to be carried out by using a suitable analytical method in the final product [6, 7].

A detailed literature survey revealed that there are some analytical methods reported for the estimation of drotaverine either individually or in combination with other drugs like HPTLC [8], spectrophotometric [9–14], by derivative spectrophotometry [15], and by HPLC [16–32]. The route of synthesis of drotaverine and possible degradants resulted in four known impurities, Impurity 1, Impurity 2, Impurity 3, and Impurity 4, which are not reported in any of the pharmacopeia.

To date, there is not a single method that has been reported for the determination of the impurities either in bulk drugs or in pharmaceutical formulations of drotaverine. It is necessary to develop a stability-indicating method for drotaverine-related impurities in API and tablet dosage formulation.

Hence, an attempt has been made to develop an accurate, rapid, specific, and reproducible method for the determination of drotaverine impurities (Fig. 1) in API and in pharmaceutical dosage forms along with method validation as per ICH guidelines [33, 34]. The stability tests were also performed on the drug substance and drug product as per ICH guidelines [35, 36].
| S.No | Name       | Structure / IUPAC name                                                                 |
|------|------------|---------------------------------------------------------------------------------------|
| 1    | Drotaverine| (1Z)-1-(3,4-Diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline         |
| 2    | Impurity 1 | N-ethyl-3,4-dimethoxyaniline                                                          |
| 3    | Impurity 2 | (3,4-dimethoxyphenyl)acetic acid                                                     |
| 4    | Impurity 3 | (5,6-diethoxy-3,4-dihydroisoquinolin-1-yl) (3,4-diethoxyphenyl)methanone              |
| 5    | Impurity 4 | 2-(3,4-diethoxyphenyl)-N-[2-(3,4-diethoxyphenyl)ethyl]acetamide                      |

Fig. 1. Chemical structures of drotaverine and its impurities

**Experimental**

*Chemicals, Reagents, and Samples*

Drotaverine tablets were received from formulation research and the development laboratory of Dr. Reddy’s Laboratories Ltd., IPDO, Hyderabad, India. Drotaverine API and impurities were procured from RA Chem Ltd., India. Potassium dihydrogen orthophosphate was procured from Merck, Germany. HPLC grade acetonitrile and orthophosphoric acid were purchased from Merck, Germany, and high purity water was prepared by using the Millipore Milli-Q Plus purification system.
**Equipment**

A Waters HPLC system with a DAD (2996 detector and 2695 separation module with quaternary gradient) was used for method development and method validation. The output signal was monitored and processed using Waters Empower software. Weighing was performed with a Mettler XS 205 dual range (Mettler-Toledo GmbH, Greifensee, Switzerland). Photostability studies were carried out in a photostability chamber (SUN TEST XLS+, Atlas, USA). Thermal stability studies were performed in a dry air oven (Merck Pharmatech, Hyderabad, India).

**Chromatographic System**

HPLC measurements were carried out using a reversed-phase XTerra RP 18, 150 x 4.6 mm, 5 μ particle size column (Waters) operated at 25°C with gradient elution at 1.0 mL min⁻¹; UV absorbance at 230 nm; injection volume 20 µL. Mobile phase A consisted of a 3.0 pH 0.02 M potassium dihydrogen orthophosphate buffer and acetonitrile (90:10 v/v); mobile phase B consisted of a pH 3.0 pH 0.02 M potassium dihydrogen orthophosphate buffer and acetonitrile (40:60 v/v). The LC gradient program was set as: time (min)/% mobile phase B: 0.01/30, 7.5/80, 15/90, 17/30, and 20/30. Water and acetonitrile (70:30 v/v) were used as diluent for the sample preparation.

**Preparation of Standard Solution and System Suitability Solution**

A stock solution of drotaverine (1000 µg mL⁻¹) was prepared by dissolving an appropriate amount in diluent. Working solution was prepared from the above stock solution for related substances’ determination (2 µg mL⁻¹ of drotaverine) in diluent. A mixture of all impurities (2.0 µg mL⁻¹) along with drotaverine (1000 µg mL⁻¹) was prepared in diluent. Also impurity stock solutions were prepared in diluent.

**Preparation of Test Solution**

Twenty tablets’ (drotaverine label claim: 80 mg per tablet) content was weighed and the average weight of each tablet was calculated. Tablet powder equivalent to 100 mg of the active pharmaceutical ingredient (drotaverine) was transferred into a 100 mL volumetric flask. To this, 70 mL of diluent was added and sonicated for 30 minutes with intermediate shaking. The solution was then diluted to 100 mL with diluent and centrifuged at 3000 rpm for 10 min. The supernatant (1000 µg mL⁻¹ of drotaverine) was collected and used as sample solution.

**Method Validation**

The proposed method was validated as per ICH guidelines [34].

**System Suitability**

System suitability parameters were performed to verify the system performance. The system precision was determined on six replicate injections of the standard preparation. All of the important characteristics, including the relative standard deviation (RSD), peak tailing, and theoretical plate number, were measured. The resolutions between the impurities were measured by injecting the system suitability solution. All of these system suitability parameters covered the system, method, and column performance.
**Specificity**

Stress studies were performed at an initial concentration of 1000 µg mL$^{-1}$ of drotaverine in API and a formulated sample to provide the stability-indicating property and specificity of the method. Intentional degradation was attempted by the stress conditions when exposed to acid (0.1 N HCl for 20 min at 60°C), base (0.1 N NaOH for 20 min at 60°C), oxidation (3% hydrogen peroxide for 20 min at 60ºC), heat (exposed at 105°C for 3 h), humidity (exposed to 90% RH for 7 days), and photolytic stress (1.2 million lux hours followed by 200 watt hours m$^{-2}$).

**Precision**

The precision for the determination of the impurities was checked by injecting six individual preparations of drotaverine (1000 µg mL$^{-1}$) test preparations spiked with 2.0 µg mL$^{-1}$ of Impurity 1, Impurity 2, Impurity 3, and Impurity 4, and calculated the RSD of each impurity content and retention time. The intermediate precision of the method was also evaluated using different analysts and a different instrument in the same laboratory on a different day. Also, the precision and intermediate precision study was performed by spiking 2.0 µg mL$^{-1}$ of drotaverine on the placebo as per test preparation.

**Accuracy**

The accuracy of the method was demonstrated at five different concentration levels in triplicate. The analysis was carried out by spiking all of the impurities on the formulation sample at 0.1, 0.2, 0.5, 0.75, and 1.0% of the drotaverine concentration (1000 µg mL$^{-1}$). Also, the accuracy study was performed by spiking drotaverine on the placebo at the above-mentioned levels. The percentage mean recoveries at each level for all of the impurities and drotaverine were calculated.

**Limit of Detection (LOD) and Limit of Quantification (LOQ)**

The LOD and LOQ for Impurity 1, Impurity 2, Impurity 3, Impurity 4, and drotaverine were estimated at a S/N of 3:1 and 10:1, respectively, by injecting a series of dilute solutions with known concentrations. The precision and accuracy studies were also carried out at the LOQ level.

**Linearity**

The linearity solutions were prepared from stock solutions at six concentration levels from the LOQ to 1.0% of the analyte concentration. The peak area versus concentration data were subjected to least-squares linear regression analysis. The calibration curve was drawn by plotting impurity areas against the concentration expressed in µg mL$^{-1}$.

**Robustness**

To determine the robustness of the developed method, experimental conditions were deliberately changed and the resolution between drotaverine & its impurities, tailing factor, and theoretical plates of the drotaverine peak were evaluated.

To study the effect of the flow rate on the developed method, it was changed from 1.0 mL min$^{-1}$ to 0.8 and 1.2 mL min$^{-1}$. The effect of column temperature on the developed method was studied at 20 and 30°C (instead of 25°C). The effect of pH was studied by varying ±
0.2 pH units (i.e. 2.8 and 3.2) and the mobile phase composition was changed ±10% from the initial composition. In all of the above-varied conditions, the component of the mobile phase was held constant.

**Stability in Solution and in the Mobile Phase**

Drotaverine-spiked samples (impurities spiked at 0.2% of the analyte concentration) were prepared in the diluent, leaving the test solutions at room temperature. The spiked samples were injected at 0, 24, 48 hrs time intervals. The impurity content was calculated, and the consistency in the content of each impurity at each interval was checked. The prepared mobile phase was kept constant during the study period. The mobile phase study was demonstrated by injecting the freshly prepared sample solution at different time intervals (0–2 days).

**Results and Discussion**

**Optimization of Chromatographic Conditions**

The main criterion for developing an RP-HPLC method for the determination of impurities in drotaverine pharmaceutical dosage form was to be in a single run, with emphasis on the method being accurate, reproducible, robust, stability-indicating, linear, free of interference from other formulation excipients, and convenient enough for routine use in quality control laboratories.

Individual stock solutions of drotaverine and its impurities were scanned in a photodiode array detector in the range of 200 to 400 nm and checked the spectra of each component. From the spectra (Fig. 2), all the impurities had an absorbance maximum at about 230 nm. Hence 230 nm was selected for the estimation of drotaverine impurities.

The drotaverine sample preparation (1000 µg mL\(^{-1}\)) spiked with all the impurities (2.0 µg mL\(^{-1}\)) and placebo preparation was subjected to separation by RP-HPLC. Initially, the separation of all the peaks was studied by using a reversed-phase XTerra RP18, 150 x 4.6 mm, 5 µ particle size column with isocratic elution. The mobile phase consisted of a 0.02 M potassium dihydrogen orthophosphate buffer of pH 3.0 (pH-adjusted with dilute orthophosphoric acid solution) and acetonitrile in the ratio of 50:50 (v/v). A 1.0 mL/min flow rate was selected to achieve the separation of all the peaks and the column oven temperature was maintained at 25°C. It was observed that impurities 1, 2, and a few unknown peaks eluted close to the void volume with improper separation. It was also observed that one unknown impurity peak was eluted at the retention time of 25 minutes. To achieve separation between the early eluting peaks, the buffer concentration was increased to 70% instead of 50%, but the separation was not up to the mark and one unknown impurity peak eluted at 50 minutes. Separation was tried further by decreasing the flow rate, which resulted in a longer run time.
Based on above experiments, the isocratic program was replaced with the gradient program in an effort to achieve high resolution between the known impurities and all degradant peaks within a shorter run time. With the same column, different combinations of mobile phase A and B were studied with different gradient programmes to optimize the method. Finally, the chromatographic separation was achieved and the finalized conditions were mentioned in the chromatographic system under the “Experimental” section. All the impurities were well-separated with a resolution greater than 2, typical retention times of drotaverine, Impurity 1, Impurity 2, Impurity 3, and Impurity 4 were 7.360 min, 2.664 min, 6.617 min, 10.447 min, and 11.382 min, respectively. No chromatographic interference due to the blank (diluent) and other excipients (placebo) at the retention time of drotaverine and all impurities were observed. The typical overlay chromatogram of the blank and system suitability solution, placebo, and spiked sample is shown in Fig. 3a & 3b.

**Response Factor**

The measurement of the response factor for each impurity determination is important when the calculations are being made on a relative percent basis. Relative response factor was calculated from the ratio of the slope of each impurity against the slope of the drotaverine standard. Hence an authentic sample of drotaverine and its impurities were dissolved in the diluent and prepared series of solutions. The details of solution preparations were mentioned in the "Linearity" section under “Experimental.” The slope and response factor values are mentioned in Table 6.
Fig. 3a. HPLC overlay chromatograms of blank and system suitability solution

Fig. 3b. HPLC overlay chromatograms of placebo and spiked sample
Method Validation

After the development of the method, it was subject to method validation as per ICH guidelines [34]. The method was validated to demonstrate that it is suitable for its intended purpose by the standard procedure to evaluate the adequate validation characteristics (system suitability, specificity, accuracy, precision, linearity, robustness, ruggedness, solution stability, LOD, LOQ, and stability-indicating capability).

System suitability

The percentage relative standard deviation (RSD) of the area from six replicate injections was below 5.0% (diluted standard solution, 2.0 µg mL\(^{-1}\) of drotaverine). Low values of the RSD for replicate injections indicate that the system is precise. The results of other system suitability parameters such as resolution, peak tailing, and theoretical plates are presented in Table 1. As seen from this data, the acceptable system suitability parameters would be as follows: the relative standard deviation of replicate injections is not more than 5.0%, resolution between the impurities is 2.5, the tailing factor for drotaverine is not more than 1.5, and the theoretical plates are not less than 10000.

| Parameter                                      | Peak area (RSD %)* | Theoretical plates* | Tailing Factor* | Resolution 1 | Resolution 2 |
|------------------------------------------------|--------------------|---------------------|-----------------|--------------|--------------|
| As such method                                 | 0.6                | 32729               | 1.1             | 3.5          | 4.2          |
| Low flow rate (0.8 ml/min)                     | 0.4                | 29947               | 1.0             | 2.9          | 4.0          |
| High flow rate (1.2 ml/min)                    | 0.8                | 29838               | 1.0             | 2.2          | 3.9          |
| Low column temperature (20°C)                  | 0.2                | 33092               | 1.1             | 2.8          | 3.8          |
| High column temperature (30°C)                 | 0.5                | 32779               | 1.1             | 3.4          | 4.1          |
| Low pH (2.8)                                   | 0.3                | 29712               | 1.0             | 3.1          | 3.7          |
| High pH (3.2)                                  | 0.7                | 29878               | 1.0             | 2.8          | 3.5          |
| Low Organic phase composition in mobile phase B (−10%) | 0.6                | 23831               | 1.0             | 3.3          | 4.2          |
| High Organic phase composition in mobile phase B (+10%) | 0.5                | 33297               | 1.1             | 3.0          | 3.7          |

* Determined on six values.
Resolution 1: Resolution between drotaverine and Impurity 2.
Resolution 2: Resolution between Impurity 3 and Impurity 4.

Specificity

All forced degradation samples were analyzed with the aforementioned HPLC conditions using a PDA detector to monitor the homogeneity and purity of the drotaverine peak and its related impurities. Individual impurities, the placebo, and drotaverine were verified and proved to be non-interfering with each other, thus proving the specificity of the method.

Figure 3b shows that there is no interference at the RT (retention time) of drotaverine and all known impurities from the other excipients. Degradation was not observed in the acid stress, humidity stress, and photo stress studies. Significant degradation was observed in the base stress, peroxide stress, and heat stress studies. It is interesting to note that all
the peaks were well-resolved due to degradation from the peaks of drotaverine and its impurities. Further, the peak purity of drotaverine and its impurities was found to be homogeneous based on the evaluation parameters such as purity angle and purity threshold using Waters Empower Networking Software. The verification of peak purity indicates that there is no interference from the degradants, facilitating error-free quantification of the drotaverine impurities. Also, the mass balance of the stressed samples was found to be more than 98%. Thus, the method is considered to be “stability-indicating”. The specificity results are shown Table 2 and base, peroxide, and heat stress chromatograms are shown in Figs. 4a, 4b & 4c.

**Tab. 2.** Forced degradation data for drotaverine

| Degradation conditions | % degraded | Purity angle | Purity Threshold | Mass balance (%) |
|------------------------|------------|--------------|------------------|------------------|
| Acid Stress            | 0.9        | 0.267        | 1.957            | 99.8             |
| Base Stress            | 3.4        | 0.335        | 1.789            | 99.1             |
| Peroxide Stress        | 6.7        | 0.258        | 1.570            | 100.2            |
| Heat Stress            | 3.5        | 0.424        | 1.794            | 98.9             |
| Humidity Stress        | 0.4        | 0.425        | 2.241            | 99.3             |
| Photo Stress           | 0.6        | 0.344        | 1.883            | 99.2             |

**Fig. 4a.** Typical chromatogram and purity plot of base-stressed sample
Fig. 4b. Typical chromatogram of peroxide-stressed sample

Fig. 4c. Typical chromatogram of heat-stressed sample
**Precision**

In the method precision study, the RSD was within 0.5 for Impurity 1, 1.0 for Impurity 2, 1.6 for Impurity 3, 0.7 for Impurity 4, and 0.5 for drotaverine, respectively. In the intermediate precision study, the RSD was within 2.4 for Impurity 1, 2.6 for Impurity 2, 2.5 for Impurity 3, 1.3 for Impurity 4, and 2.4 for drotaverine, respectively. Also, the RSD for the retention times for each component from both the precision and intermediate precision study were within 0.3. The results are shown in Tables 3a & 3b.

**Tab. 3a.** Results of method precision (analyst 1, instrument 1, column 1, and day 1)

| Preparation | Impurity 1 | Impurity 2 | Impurity 3 | Impurity 4 | Drotaverine |
|-------------|------------|------------|------------|------------|-------------|
| Prep-1      | 0.202      | 0.194      | 0.197      | 0.205      | 0.196       |
| Prep-2      | 0.200      | 0.197      | 0.199      | 0.205      | 0.195       |
| Prep-3      | 0.200      | 0.194      | 0.202      | 0.206      | 0.198       |
| Prep-4      | 0.202      | 0.197      | 0.202      | 0.205      | 0.197       |
| Prep-5      | 0.202      | 0.192      | 0.206      | 0.208      | 0.197       |
| Prep-6      | 0.202      | 0.196      | 0.204      | 0.204      | 0.196       |
| Avg         | 0.202      | 0.195      | 0.202      | 0.206      | 0.197       |
| %RSD        | 0.5        | 1.0        | 1.6        | 0.7        | 0.5         |
| % RSD for retention time | 0.3 | 0.2 | 0.2 | 0.3 | 0.1 |

**Tab. 3b.** Results of intermediate method precision (analyst 2, instrument 2, column 2, and day 2)

| Preparation | Impurity 1 | Impurity 2 | Impurity 3 | Impurity 4 | Drotaverine |
|-------------|------------|------------|------------|------------|-------------|
| Prep-1      | 0.199      | 0.208      | 0.198      | 0.212      | 0.197       |
| Prep-2      | 0.203      | 0.210      | 0.200      | 0.210      | 0.209       |
| Prep-3      | 0.195      | 0.199      | 0.203      | 0.215      | 0.205       |
| Prep-4      | 0.193      | 0.201      | 0.210      | 0.207      | 0.199       |
| Prep-5      | 0.202      | 0.199      | 0.198      | 0.213      | 0.201       |
| Prep-6      | 0.205      | 0.210      | 0.208      | 0.210      | 0.197       |
| Avg         | 0.200      | 0.205      | 0.203      | 0.211      | 0.201       |
| %RSD        | 2.4        | 2.6        | 2.5        | 1.3        | 2.4         |
| % RSD for retention time | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 |

**Accuracy**

The recovery of all of the four impurities and drotaverine from the finished pharmaceutical dosage form ranged from 85.0% to 115.0%. The summary of % recovery for each individual impurity is mentioned in Table 4.
Tab. 4. Accuracy of the method

| Spike Level | Impurity 1 | Impurity 2 | Impurity 3 | Impurity 4 | Drotaverine |
|-------------|------------|------------|------------|------------|-------------|
| 0.1%        | 100.6±0.6  | 103.4±0.8  | 97.8±2.1   | 99.9±1.2   | 97.5±0.4    |
| 0.2%        | 100.1±0.4  | 101.4±1.6  | 102.7±0.2  | 97.9±1.4   | 99.5±0.9    |
| 0.5%        | 100.6±1.1  | 105.5±0.7  | 101.1±0.4  | 95.2±0.8   | 100.2±0.5   |
| 0.75%       | 100.9±0.9  | 104.7±1.3  | 102.6±0.7  | 95.7±0.4   | 98.5±0.5    |
| 1.0%        | 100.4±0.3  | 103.2±1.9  | 103.0±0.5  | 97.9±0.9   | 99.2±0.8    |

* Mean ± standard deviation for three determinations

Limit of Detection (LOD) and Limit of Quantification (LOQ)

LOD values were achieved at 0.076, 0.083, 0.110, 0.076, and 0.107 µg mL\(^{-1}\) for Impurity 1, Impurity 2, Impurity 3, Impurity 4, and drotaverine, respectively. LOQ values were achieved at 0.231, 0.251, 0.334, 0.230, and 0.324 µg mL\(^{-1}\) for Impurity 1, Impurity 2, Impurity 3, Impurity 4, and drotaverine, respectively. The % RSD of precision at the LOQ concentration for Impurity 1, Impurity 2, Impurity 3, Impurity 4, and drotaverine was found to be below 5.0. The results of precision at the LOQ level is shown in Table 5.

Tab. 5. Results of precision at limit of quantification

| Preparation | Impurity 1 | Impurity 2 | Impurity 3 | Impurity 4 | Drotaverine |
|-------------|------------|------------|------------|------------|-------------|
| Prep-1      | 0.025      | 0.023      | 0.023      | 0.033      | 0.032       |
| Prep-2      | 0.026      | 0.022      | 0.025      | 0.034      | 0.030       |
| Prep-3      | 0.025      | 0.025      | 0.024      | 0.032      | 0.029       |
| Prep-4      | 0.024      | 0.024      | 0.025      | 0.033      | 0.032       |
| Prep-5      | 0.027      | 0.023      | 0.024      | 0.031      | 0.033       |
| Prep-6      | 0.023      | 0.022      | 0.022      | 0.032      | 0.031       |
| Avg         | 0.025      | 0.023      | 0.024      | 0.033      | 0.031       |
| %RSD        | 0.7        | 5.0        | 4.9        | 3.2        | 4.7         |

Linearity

Linearity regression analysis demonstrated the acceptability of the method for the quantitative determination range of the LOQ (0.231, 0.251, 0.334, 0.230, and 0.324 µg mL\(^{-1}\) for Impurity 1, Impurity 2, Impurity 3, Impurity 4, and drotaverine, respectively) to 10 µg mL\(^{-1}\). The correlation coefficient was found to be more than 0.997. The regression statistics are shown in Table 6.

Robustness

No significant effect was observed on the system suitability parameters such as resolution, RSD, tailing factor, or the theoretical plates of drotaverine when small, but deliberate changes were made to the chromatographic conditions. The results are presented in Table 1, along with the system suitability parameters of normal conditions. Thus, the method was found to be robust with respect to variability in applied conditions.
**Stability in Solution and in the Mobile Phase**

No significant changes were observed in the content of impurities, namely Impurity 1, Impurity 2, Impurity 3, and Impurity 4 during the solution stability and mobile phase stability experiments when performed using the impurities method. The solution stability and mobile phase stability experiment data confirm that the sample solution and mobile phases used during the impurity determination were stable for at least 48 h.

**Tab. 6.** Regression statistics and relative response factor results

| Substance   | Linearity range (μg mL⁻¹) | Correlation coefficient (R²) | Y-intercept | Bias in % | Slope        | Relative response factor |
|-------------|---------------------------|-----------------------------|-------------|-----------|--------------|-------------------------|
| Impurity 1  | 0.251–10.033              | 1.000                       | 3.0         | 39419.7   | 1.04         |                         |
| Impurity 2  | 0.231–9.995               | 1.000                       | 1.7         | 31872.2   | 0.84         |                         |
| Impurity 3  | 0.230–10.089              | 1.000                       | 1.8         | 41923.2   | 1.10         |                         |
| Impurity 4  | 0.334–10.011              | 1.000                       | 1.8         | 49327.6   | 1.30         |                         |
| Drotaverine | 0.324–10.050              | 1.000                       | 1.5         | 37977.5   | –            |                         |

**Conclusion**

The gradient HPLC method developed for the determination of drotaverine impurities in both bulk drug and pharmaceutical dosage form was precise, accurate, and specific. The method is validated as per ICH guidelines and found to be specific, precise, linear, accurate, rugged, and robust. The developed method can be used for the stability analysis of both drotaverine API and formulated samples.

**Acknowledgement**

The authors wish to thank the management of Dr. Reddy’s group for supporting this work. Authors wish to acknowledge the formulation development group for providing the samples for our research.

Dr. Reddy’s internal publication number for this manuscript is PUB-00262-13.

**Authors’ Statement**

**Competing Interests**

The authors declare no conflict of interest.

**References**

[1] Oneil MJ, Smith A, Heckelman PE. The Merck Index (Thirteenth Edition). 2001; 349.

[2] Tömösközi Z, Finance O, Arányi P. Drotaverine interacts with the L-type Ca²⁺ channel in pregnant rat uterine membranes. Eur J Pharmacol. 2002; 55–60. http://dx.doi.org/10.1016/S0014-2999(02)01993-3
[3] Sethi SD. Textbook of Pharmacology (Elsevier). 2004; 831-40.

[4] Gorog S. Identification and Determination of Impurities in Drugs. Talanta. 1997; 44: 1517–1526. http://dx.doi.org/10.1016/S0039-9140(96)02179-0

[5] Sanjay BB, Bharati RK, Yogini SJ, Atul AS. Impurity profile: Significance in active pharmaceutical ingredient. Eurasian J Anal Chem. 2007; 2: 32–53.

[6] ICH – Q3A (R2) (2006). Impurities in New Drug Substances.

[7] ICH – Q3B (R2) (2006). Impurities in New Drug Products.

[8] Chitlange S, Kumar N, Kulkarni P, Wankhede S. Stability-indicating HPTLC method for simultaneous estimation of Drotaverine and Nimesulide in pharmaceutical dosage form. Der Pharma Chemica. 2009; 1: 50–58.

[9] Bhabani Shankar Khuntia, Susanta Kumar Panda. Development and Validation of New Analytical Method for Estimation of Drotaverine in Bulk and Pharmaceutical Dosage Form by UV Spectrophotometry. IJPI's Journal of Analytical Chemistry. 2011; 1 (6): 1–8.

[10] Vivek S, Rajmane, Gandhi SV, Upasana PP, Mahima RS. Simultaneous determination of drotaverine hydrochloride and Aceclofenac in tablet dosage form by spectrophotometry. Eurasian J Anal. Chem. 2009; 4: 184–190.

[11] Metwally FH. Simultaneous determination of nifuroxazide and drotaverine hydrochloride in pharmaceutical preparations by bivariate and multivariate spectral analysis Spectrochim Acta A. 2008; 69: 343–349. http://dx.doi.org/10.1016/j.saa.2007.04.004

[12] Amina AS, El-Sheikh R, Zahranb F, El-fetouh Goudab AA. Spectrophotometric determination of pipazethate HCl, dextromethorphan HBr and drotaverine HCl in their pharmaceutical preparations. Spectrochim Acta A. 2007; 67: 1088–1093. http://dx.doi.org/10.1016/j.saa.2006.09.027

[13] Abdellatf E, Ayad M, Soliman M, Youssef F. Spectrophotometric and spectrodensitometric determination of paracetamol and drotaverine HCl in combination. Spectrochim Acta A. 2007; 66: 1147–1151. http://dx.doi.org/10.1016/j.saa.2006.05.028

[14] Tulja Rani G, Gowri Sankar D, Kadgopathi P, Suthakaran R, Satyanarayana B. Visible Spectrophotometric Methods for the Determination of Drotaverine Hydrochloride in Bulk and in Pharmaceutical Formulations. Int J PharmTechRes. 2010; 2: 1787–1791.

[15] Panikumar DA, Sunitha Gurrala, Venkat Raju Yeradesi, Sathesh Babu RP, Subrahmanyam VSC. Development of Dissolution Test Method for Drotaverine Hydrochloride/Mefenamic Acid Combination Using Derivative Spectrophotometry. Trop J Pharm Res. 2013; 12: 227–232.
[16] Premanand DC, Senthilkumar KL, Senthilkumar B, Saravanakumar M, Thirumurthy R. New RP-HPLC Method Development and Validation of Mefenamic Acid and Drotaverine Hydrochloride in Combined Dosage Form. The Journal of Pharmacy. 2011; 1: 7–11.

[17] Radha Krishnan K, Chandra Sekhar U, Vamsi Krishna CH, Rajagopal Reddy PDV, Hari P, Chennaiah G. Stability indicating validated method for the simultaneous estimation of Drotaverine HCl and Mefenamic acid in pure and pharmaceutical dosage form by RP-HPLC. Int J Pharm Res Life Sci. 2013; 1: 59–71.

[18] Atul P, Ashwini D, Shrikant F, Ratnakar A. A Validated Reverse Phase HPLC Method for Simultaneous Determination of Drotaverine Hydrochloride and Paracetamol in Tablet Dosage Form. Int J Pharm Sci. 2010; 2: 904–908.

[19] Kirti ST, Rajesh MJ, Purushotam KS, Mrinalini CD. A validated normal phase HPLC method for simultaneous determination of drotaverine hydrochloride and omeprazole in pharmaceutical formulation. Asian J Pharm Clin Res. 2010; 1: 20–24.

[20] Azhlwar S, Ravi TR. Stability indicating HPLC method for simultaneous determination of Drotaverine and Aceclofenac. Int J Pharm Pharm Sci. 2011; 3: 245–250.

[21] Syal PK, Sahoo M, Ingale KD, Ingale SS, Choudhari VP, Kuchekkar BS. Development and validation of a RP-HPLC-PDA method for simultaneous estimation of Drotaverine and Etoricoxib in tablet and its application for dissolution studies. Der Pharma Chemica. 2010; 2: 93–102.

[22] Panigrahi D, Ganesh P, Sharma R. Study of stressed degradation behavior of drotaverine and development of a validated stability-indicating HPLC assay method. Der Pharma Chemica. 2012; 4: 847–853.

[23] Kabeer AS, Sachin DP. Stability indicating rapid RP-HPLC method for the determination of Drotaverine hydrochloride, Domperidone and paracetamol in pharmaceutical dosage forms. Der Pharmacia Lettre. 2010; 2: 355–364.

[24] Patel JD, Patel BA, Vaghela VM, Patel LJ, Patel PU. RP-HPLC method for the simultaneous determination of mefenamic acid and drotaverine hydrochloride in tablet dosage form. Int J Pharm Res. 2009; 1: 35–39.

[25] Sharma R, Panigrahi D. Development and validation of an RP-HPLC method for simultaneous analysis of drotaverine and omeprazole in a tablet dosage form. Acta Chromatogr. 2008; 20: 439–450. http://dx.doi.org/10.1556/AChrom.20.2008.3.10

[26] Shaikh KA, Patil SD. Stability indicating rapid RP-HPLC method for the determination of drotaverine hydrochloride, domperidone and paracetamol in pharmaceutical dosage forms. Der Pharmacia Lettre. 2010; 2: 355–364.

[27] Bolagi OO, Onyeji CO, Ogunbamila FO, Ogunbona FA, Ogunlana EO. High-performance liquid chromatographic method for the determination of drotaverine in human plasma and urine. J Chromatogr. 1993; 622: 93–97. http://dx.doi.org/10.1016/0378-4347(93)80254-2
[28] Permanand DC, Senthilkumar KL. Simultaneous estimation of mefenamic acid and drotaverine HCl in combined dosage form by RP-HPLC method and validation of the developed method. Der Pharm Chemica. 2010; 2: 170–177.

[29] Devivelkar PP, Bari SB. High performance liquid chromatographic estimation of drotaverine hydrochloride and mefenamic acid in human plasma. Iranian J Pharm Res. 2009; 8: 209–215.

[30] Azhlwar S, Ravi TK. Stability indicating HPLC method for simultaneous determination of drotaverine and aceclofenac. Int J Pharm Sci. 2011; 3: 245–250.

[31] Metwally FH, Abdelkawy M, Naguib IA. Determination of nifuroxazide and drotaverine hydrochloride in pharmaceutical preparations by three independent analytical methods. J AOAC Int. 2006; 89: 78–87. http://www.ncbi.nlm.nih.gov/pubmed/16512232

[32] Panigrahi D, Sharma R. Development and validation of an RPHPLC method for simultaneous analysis of drotaverine and omeprazole in a tablet dosage form. Acta Chromatogr. 2008; 20: 439–450. http://dx.doi.org/10.1556/AChrom.20.2008.3.10

[33] Rajagopalan R. Review of Regulatory Guidance on Impurities. Sep Sci Technol. 2004; 5: 27–37. http://dx.doi.org/10.1016/S0149-6395(03)80004-1

[34] ICH – Q2 (R1) (2005). Guideline on Validation of Analytical Procedure: Text and Methodology.

[35] ICH – Q1A (R2) (2003). Stability Testing of New Drug Substances and Products.

[36] ICH – Q1B (1996). Photo Stability Testing of New Drug Substances and Products.